Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04788823 · ClinicalTrials.gov registry record · Phase 4
The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal
A Phase 4 study of Vasectomy Reversal, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
- Active
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04788823: Active Phase 4 study of Vasectomy Reversal, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
NCT04788823 is a Phase 4 study of Vasectomy Reversal that is active but no longer recruiting, run by Charitable Union for the Research and Education of Peyronie's Disease. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04788823, a Phase 4 study of Vasectomy Reversal, is active but no longer recruiting, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
1. Determine impact of prednisone on semen parameters post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols). 2. Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols). 3. Assess adverse events with prednisone utilization
Primary Outcome
Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Conditions Studied
Interventions
- DRUG Prednisone
Study Locations (1)
Utah
- Cure PD - Orem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2026-02 |
| Phase | Phase 4 |
What the registry record for NCT04788823 still lists
NCT04788823 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Vasectomy Reversal appearing as the primary indexed condition, and to 1 intervention - of which Prednisone is the first listed.
NCT04788823 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04788823 about?
NCT04788823 is a clinical study titled "The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal". 1. Determine impact of prednisone on semen parameters post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols). 2. Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort...
What is the current status of trial NCT04788823?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-02-24. Estimated completion is 2026-02.
What conditions does trial NCT04788823 study?
This clinical trial studies the following conditions: Vasectomy Reversal.
What interventions are being tested in trial NCT04788823?
The interventions under investigation include: Prednisone (DRUG).
Who is sponsoring clinical trial NCT04788823?
This trial is sponsored by Charitable Union for the Research and Education of Peyronie's Disease, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04788823 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04788823's enrollment target sits among peer trials
100 770th of 2000 higher than 1,149 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI